JP2024041747A5 - - Google Patents

Download PDF

Info

Publication number
JP2024041747A5
JP2024041747A5 JP2023202447A JP2023202447A JP2024041747A5 JP 2024041747 A5 JP2024041747 A5 JP 2024041747A5 JP 2023202447 A JP2023202447 A JP 2023202447A JP 2023202447 A JP2023202447 A JP 2023202447A JP 2024041747 A5 JP2024041747 A5 JP 2024041747A5
Authority
JP
Japan
Prior art keywords
interleukin
expression vector
recombinant expression
amino acid
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023202447A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024041747A (ja
Filing date
Publication date
Priority claimed from JP2022559531A external-priority patent/JP7846627B2/ja
Application filed filed Critical
Publication of JP2024041747A publication Critical patent/JP2024041747A/ja
Publication of JP2024041747A5 publication Critical patent/JP2024041747A5/ja
Pending legal-status Critical Current

Links

JP2023202447A 2020-03-31 2023-11-30 新規な免疫活性インターロイキン2アナログ Pending JP2024041747A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2020-0039476 2020-03-31
KR20200039476 2020-03-31
JP2022559531A JP7846627B2 (ja) 2020-03-31 2021-03-31 新規な免疫活性インターロイキン2アナログ
PCT/KR2021/004028 WO2021201615A1 (ko) 2020-03-31 2021-03-31 신규한 면역 활성 인터루킨 2 아날로그

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022559531A Division JP7846627B2 (ja) 2020-03-31 2021-03-31 新規な免疫活性インターロイキン2アナログ

Publications (2)

Publication Number Publication Date
JP2024041747A JP2024041747A (ja) 2024-03-27
JP2024041747A5 true JP2024041747A5 (cg-RX-API-DMAC7.html) 2026-04-20

Family

ID=77930406

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022559531A Active JP7846627B2 (ja) 2020-03-31 2021-03-31 新規な免疫活性インターロイキン2アナログ
JP2023202447A Pending JP2024041747A (ja) 2020-03-31 2023-11-30 新規な免疫活性インターロイキン2アナログ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022559531A Active JP7846627B2 (ja) 2020-03-31 2021-03-31 新規な免疫活性インターロイキン2アナログ

Country Status (17)

Country Link
US (2) US11746137B2 (cg-RX-API-DMAC7.html)
EP (1) EP4130027A4 (cg-RX-API-DMAC7.html)
JP (2) JP7846627B2 (cg-RX-API-DMAC7.html)
KR (2) KR102545250B1 (cg-RX-API-DMAC7.html)
CN (2) CN115427437B (cg-RX-API-DMAC7.html)
AR (1) AR121713A1 (cg-RX-API-DMAC7.html)
AU (2) AU2021202825B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022018730A2 (cg-RX-API-DMAC7.html)
CA (2) CA3266069A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022002562A1 (cg-RX-API-DMAC7.html)
IL (1) IL295826B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022011893A (cg-RX-API-DMAC7.html)
NZ (1) NZ793819A (cg-RX-API-DMAC7.html)
PE (1) PE20221759A1 (cg-RX-API-DMAC7.html)
TW (1) TWI876021B (cg-RX-API-DMAC7.html)
WO (1) WO2021201615A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202209565B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR121713A1 (es) * 2020-03-31 2022-06-29 Hanmi Pharm Ind Co Ltd Nuevos análogos de il-2 inmunoestimulantes
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
KR20240034221A (ko) 2021-07-09 2024-03-13 브라이트 피크 테라퓨틱스 아게 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드
KR20230095612A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그
KR102445492B1 (ko) * 2021-12-24 2022-09-21 엔케이젠 주식회사 신규한 펩타이드를 포함하는 자연살해세포 대량증식용 조성물 및 이를 이용한 자연살해세포 대량증식방법
CN114853909A (zh) * 2022-05-13 2022-08-05 南京吉盛澳玛生物医药有限公司 新型IL-2与INFα和Fc融合蛋白的设计、制备及用途
IL317511A (en) 2022-06-16 2025-02-01 Cephalon Llc IL-2 immunoconjugates attenuated by anti-PD-1 antibody and their uses
CN119790064A (zh) * 2022-08-23 2025-04-08 马斯得生物有限公司 Il2变体和包括该il2变体的蛋白复合体
KR20250126198A (ko) 2024-02-15 2025-08-25 한림대학교 산학협력단 인슐린 저항성의 예방 또는 치료를 위한 약학적 조성물

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3285989A (en) * 1987-11-25 1989-06-14 Cetus Corporation Treatment of infections caused by a primary immunodeficiency with interleukin-2
AU627477B2 (en) * 1988-07-05 1992-08-27 Amgen, Inc. Interleukin ii analogs
CA2019714A1 (en) 1989-06-27 1990-12-27 Richard A. Chizzonite Process for the determination of interleukins
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
CZ305123B6 (cs) * 1999-10-04 2015-05-13 Novartis Vaccines And Diagnostics, Inc. Způsob výroby kapalného farmaceutického prostředku
WO2004022593A2 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
KR20070003934A (ko) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
CN1930300A (zh) 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
AU2007201663A1 (en) 2007-04-16 2008-10-30 Nautilus Biotech Oral dosage formulations of protease resistant polypeptides
CN102462837B (zh) 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
WO2012088446A1 (en) * 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
KR20140106452A (ko) 2013-02-26 2014-09-03 한미약품 주식회사 신규한 인슐린 아날로그 및 이의 용도
CN105722860A (zh) 2013-09-24 2016-06-29 梅迪塞纳医疗股份有限公司 白介素-2融合蛋白及其应用
MY186251A (en) 2014-01-20 2021-06-30 Hanmi Pharm Ind Co Ltd Long-acting insulin and use thereof
JP6592505B2 (ja) * 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
CN107148279B (zh) 2014-10-21 2021-09-03 赛生药品股份国际有限公司 用免疫刺激剂治疗癌症
CN104403004B (zh) * 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
KR20160134989A (ko) 2015-05-14 2016-11-24 순천향대학교 산학협력단 인간 인터류킨-2 단백질을 포함하는 약학조성물
CN107266553A (zh) * 2016-04-08 2017-10-20 南京康志制药有限公司 高效人白细胞介素ⅱ突变体融合蛋白及其应用
KR20240115933A (ko) * 2016-05-04 2024-07-26 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
CN110913954A (zh) * 2017-03-03 2020-03-24 黑曜石疗法公司 免疫疗法的组合物和方法
AU2018287317B2 (en) * 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
JP7356726B2 (ja) * 2017-09-25 2023-10-05 ディンフー バイオターゲット カンパニー リミテッド タンパク性ヘテロ二量体及びその使用
US10946068B2 (en) * 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
JP7534215B2 (ja) * 2018-01-24 2024-08-14 ベイジン パーカンズ オンコロジー カンパニー リミテッド サイトカイン融合タンパク質
CN108503714A (zh) 2018-04-10 2018-09-07 浙江科途医学科技有限公司 一种人白介素2和抗人上皮细胞黏附分子单链抗体融合蛋白及其应用
MX2020012251A (es) * 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
AU2019288496B2 (en) * 2018-06-22 2024-11-21 Cugene Inc. Interleukin-2 variants and methods of uses thereof
US12522640B2 (en) * 2018-07-24 2026-01-13 BioNTech SE IL2 agonists
SG11202005873QA (en) * 2018-09-17 2020-07-29 Gi Innovation Inc Fusion protein comprising il-2 protein and cd80 protein, and use thereof
CA3098930A1 (en) * 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
MX2021005708A (es) * 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
US20220025007A1 (en) * 2018-12-21 2022-01-27 Hanmi Pharm. Co., Ltd. Novel immunosuppressive interleukin 2
CN111944036B (zh) 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
CN114437198A (zh) 2019-12-17 2022-05-06 北京志道生物科技有限公司 白介素-2衍生物
BR112022017656A2 (pt) 2020-03-05 2022-10-18 Univ Leland Stanford Junior Variantes de il-2 concebidas
AR121713A1 (es) * 2020-03-31 2022-06-29 Hanmi Pharm Ind Co Ltd Nuevos análogos de il-2 inmunoestimulantes

Similar Documents

Publication Publication Date Title
JP2019122392A5 (cg-RX-API-DMAC7.html)
EP4272765A3 (en) Adeno-associated virus (aav) clade f vector and uses therefor
JP2023082054A5 (cg-RX-API-DMAC7.html)
SA522433360B1 (ar) L-أَسْباراجيناز مُعدل
JP2023179457A5 (cg-RX-API-DMAC7.html)
JP2014224126A5 (cg-RX-API-DMAC7.html)
JP2017212998A5 (cg-RX-API-DMAC7.html)
JP2010222379A5 (cg-RX-API-DMAC7.html)
NZ593833A (en) Extended recombinant polypeptides and compositions comprising same
JP2021505201A5 (cg-RX-API-DMAC7.html)
NZ597685A (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
JP2015525217A5 (cg-RX-API-DMAC7.html)
FI3737399T3 (fi) ATF5-peptidivariantit ja niiden käytöt
NZ596764A (en) N-glycan core beta-galactosyltransferase and uses thereof
MX2021004714A (es) Proteina cas9 modificada, y uso de la misma.
JP2020513810A5 (cg-RX-API-DMAC7.html)
EP4616705A3 (en) Peronospora resistance in spinacia oleracea
JP2024530926A5 (cg-RX-API-DMAC7.html)
JP2014193147A5 (cg-RX-API-DMAC7.html)
WO2007142582A8 (en) Fluorescent proteins and genes encoding them
EP1482047A4 (en) PROTEIN OR POLYPEPTIDE HAVING LACRYMOGENIC SUBSTANCE SYNTHASE ACTIVITY, DNA ENCODING THE PROTEIN OR THE POLYPEPTIDE, PROCESS FOR OBTAINING SAID PROTEIN OR POLYPEPTIDE, AND MOLECULE OF NUCLEIC ACIDS INHIBITING THE TRANSLATION OF MESSENGER RNA RELATING TO THE PROTEIN OR POLYPEPTIDE THE PEPTIDE
JP2003334088A5 (cg-RX-API-DMAC7.html)
JP2008517998A5 (cg-RX-API-DMAC7.html)
TW200716166A (en) Lawsonia intracellularis immunological proteins
JP2012507278A5 (cg-RX-API-DMAC7.html)